Needham Reiterates Buy on Surmodics, Maintains $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson reiterated a Buy rating on Surmodics (NASDAQ:SRDX) and maintained a $47 price target.

April 10, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterated a Buy rating on Surmodics and maintained a $47 price target.
The reiteration of a Buy rating and maintenance of a $47 price target by a reputable analyst like Mike Matson from Needham is likely to instill confidence among investors and could positively influence Surmodics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100